Abstract
Introduction In patients with incurable advanced cancer, preferences about treatment and how to spend their final days are not adequately discussed. This process of discussion is called “advanced care planning” (ACP), and timely intervention is recommended. As the communication attitude of healthcare providers is a critical factor in ACP facilitation, improving their communication attitudes may reduce patient distress, improve care satisfaction, and reduce unnecessarily aggressive treatment. Digital mobile devices are being developed for behavioral interventions due to their low space and time restrictions, and the ease of sharing information. The purpose of this study is to evaluate the effectiveness of a facilitation program utilizing a mobile app developed to improve communication between cancer patients and healthcare providers regarding ACP.
Methods and analysis This study utilizes a parallel-group, evaluator-blind, randomized controlled trial design. We plan to recruit 264 adult patients with incurable advanced cancer. Intervention group participants will use a mobile app ACP program and undergo a 30-minute interview with a trained intervention provider to discuss with the oncologist at the next patient visit. Control group participants will continue their usual treatment. The primary outcome is the oncologist’s communication behavior score assessed using audio recordings of the consultation. The secondary outcomes include communication between patients and oncologists and the patients’ distress, quality of life, care goals and preferences, and medical care utilization. We will use a full analysis set with the registered participant population who received at least a part of the intervention.
Ethics and dissemination The study protocol was reviewed and approved by the Scientific Advisory Board of the Japan Supportive, Palliative and Psychosocial Oncology Group (Registration No. 2104) and the Institutional Review Board of the National Cancer Center Hospital (registration No. 2020-500). The results of the RCT will be published in peer-reviewed scientific journals and presented at scientific meetings.
Strengths and limitations of this study
Randomized controlled trials using mobile apps for behavior change and psychological interventions are increasing, and this study is unique in its focus on facilitating communication about advanced care planning (ACP).
The intervention will include mobile apps which can be used in environments the participants find relaxing and engaging. The benefit is particularly significant for patients with advanced cancer who need to express their values and what is crucial to them.
There is currently no gold standard for evaluating ACP discussions between patients and healthcare providers. The methods facilitate ACP discussions in various aspects of this study to produce a variety of practical insights.
The timing of introducing ACP discussions must be individualized to each patient, and it is anticipated that some participants may find this intervention burdensome. Therefore, more careful ACP referrals are needed, and qualitative exploration of study dropouts is needed.
Multiple intervention components make it difficult to determine which is most effective. Individualized assessments of app usage, intervention adherence, and patient satisfaction could clarify the challenges and help determine next steps.
Competing Interest Statement
All authors declare that they have no competing interests regarding this work. BN reports grants from Ono Pharmaceutical and Takeda Pharmaceutical, and personal fees from Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi Sankyo, and Taiho Pharmaceutical. TA reports grants from Daiichi Sankyo, Eisai, Fujifilm RI Pharma, MSD, Otsuka Pharmaceutical, and Shionogi, personal fees from Igaku-Shoin, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Janssen Pharmaceutical, Kyowa Kirin, Eli Lilly, MSD, Meiji Seika Pharma, Mochida Pharmaceutical, NIPRO, Nippon Zoki Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical and Viatris, and pending patents (2019-017498 & 2020-135195). TY reports grants or contracts from AC Medical Inc., A2 Healthcare Corporation, EP Croit Co., Ltd., ClinChoice., Japan Tobacco Inc., Japan Media Corporation, Medidata Solutions, Inc., Ono Pharmaceutical Co., Ltd., Asahi Intecc Co., Ltd., 3H Clinical Trial Inc., Medrio, Inc., Nipro Corporation, Intellim Corporation, Welby Inc., 3H Medi Solution Inc., Nipro Corporation, BaseConnect Inc., Nobori Ltd., Puravida Technologies LLC., and Hemp Kitchen Inc. and grants to the affiliated institutions from Kyowa Kirin Co., Ltd., Tsumura & CO., Daiichi Sankyo Company, Limited., Otsuka Pharmaceutical Co., Ltd., and Eisai Co., Ltd., and consulting fees from EPS Corporation., Japan Tobacco Inc., Medidata Solutions, Inc., Ono Pharmaceutical Co., Ltd., Kowa Company, Ltd., Chugai Pharmaceutical Co., Ltd., Tsumura & Co., Daiichi Sankyo Company, Limited., Eisai Co., Ltd., Asahi Intecc Co., Ltd., Asahi Kasei Pharma Corporation, 3H Clinical Trial Inc., Intellim Corporation, Takeda, AstraZeneca, Sonire Therapeutics Inc., Seikagaku Corporation, and Merck & Co., Inc., and personal fees from Nipro Corporation.
Clinical Trial
UMIN000045305
Funding Statement
This study is funded by the Health Labour Sciences Research Grant from The Ministry of Health Labour and Welfare Japan (Funding ID: 20EA1010) and Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (Funding ID: 19H03878) to PI Yosuke Uchitomi. These funders were not involved in the design of this study and will not play any role in its conduct, analysis, interpretation of data, or decision to submit results. The work is endorsed by the Japan Supportive, Palliative and Psychosocial Oncology Group (J-SUPPORT) as the J-SUPPORT 2104 study, funded by the National Cancer Center Research and Development Fund (30A-11).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Institutional Review Board of the National Cancer Center Hospital (registration No. 2020-500)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Trial status The study is currently recruiting participants, with enrollment scheduled to run through March 2023 and follow-up scheduled through September 2023.
Trial registration number The protocol was registered on August 31, 2021, at the UMIN Clinical Trials Registry (UMIN000045305) and on September 16, 2021, at ClinicalTrials.gov (NCT05045040).
Data statement The study protocol, data definition tables, and dataset will be uploaded to the UMIN-Individual Case Data Repository at https://www.umin.ac.jp/icdr/index-j.html.
Protocol version The protocol was updated to version 2.0 on May 19, 2022.
Data Availability
The study protocol, data definition tables, and dataset will be uploaded to the UMIN-Individual Case Data Repository
